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OBJECTIVE—Engraftment and function of human islet cell
implants is considered to be dependent on their rapid and
adequate revascularization. Studies with rodent islet grafts have
shown that vascular endothelial growth factor (VEGF) expres-
sion by -cells can promote this process. The present work
examines whether human islet preparations produce VEGF as
well as interleukin (IL)-8, another angiogenic protein, and as-
sesses the role of contaminating duct cells in VEGF and IL-8–
mediated angiogenesis.
RESEARCH DESIGN AND METHODS—Human islet and pan-
creatic duct cell preparations are compared for their respective
expression and production of VEGF and IL-8 during culture as well
as following transplantation in nonobese diabetic (NOD)/scid mice.
The associated angiogenic effects are measured in an in vitro aortic
ring assay and in an in vivo chick embryo chorioallantoic membrane
assay.
RESULTS—Cultured pancreatic duct cells expressed 3- and
10-fold more VEGF and IL-8, respectively, than cultured human
islet endocrine cells and released both proteins at angiogenic
levels. The angiogenic effect of puriﬁed duct cells was higher
than that of puriﬁed endocrine islet cells and was completely
blocked by a combination of IL-8 and VEGF antibodies. Human duct
cell implants under the kidney capsule of NOD/scid mice expressed
higher levels of IL-8 and VEGF than human islet cell implants and
induced circulating IL-8 and VEGF levels during the ﬁrst day
posttransplantation.
CONCLUSIONS—Human duct cell–released IL-8 and VEGF
may help revascularization of currently used human islet cell
grafts. Further work should examine whether and when this
effect can prevail over other inﬂammatory and immune inﬂu-
ences of this cell type. Diabetes 57:2128–2136, 2008
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slet cell transplant protocols have been designed to
restore type 1 diabetes in patients, but the function
of the implants was found to progressively decrease,
leading to 15% insulin-independent recipients after
5 years (1). Several variables can explain this loss in
metabolic efﬁcacy. We have observed that the functional
-cell mass in insulin-independent recipients at posttrans-
plant month 12 is only 20–30% of that in normal control
subjects (2). It is so far unknown to which extent this
quantitative deﬁcit results from an insufﬁcient mass before
injection, from poor engraftment, and/or from destruction
by inﬂammation and immune reaction during the ﬁrst year.
There is evidence that -cell loss is considerable during
the ﬁrst days posttransplantation (3), which has intensiﬁed
attention to the process of revascularization in the islet
cell implant (4,5).
In their normal pancreatic habitat, islet cells are embed-
ded in a dense microvascular network that should meet
the high oxygen and nutrient needs of the endocrine cells.
The islet isolation process and the subsequent in vitro
steps, however, disrupt capillary structures and their
association with endocrine cells, making the formation of
new vessels necessary for adequate graft survival. In
rodent models, the islet blood ﬂow appears restored
within 1–2 weeks after transplantation (5); during the ﬁrst
posttransplant week, transplanted cells seem thus depen-
dent on adequate diffusion of oxygen and nutrients, while
mechanisms should be initiated to start sprouting of
vessels into their intrahepatic sites. New-vessel formation
can be induced and directed by factors released by the
tissue to be irrigated (6). Islet -cells are known to
produce vascular endothelial growth factor (VEGF), and
several studies have been reported on the beneﬁcial effects
of an increased VEGF expression or availability on sur-
vival of transplanted islets in rodents (7). However, it
remains unclear to which extent VEGF release from
normal -cells succeeds in rapidly inducing an adequate
blood supply to the implants. Moreover, such angiogenic
action might be less pronounced in human islet cell
preparations, since they contain much lower percentages
of -cells than isolated rodent islets (8). Our transplant
protocols are conducted with cultured human islet cell
grafts in which duct cells represent the main contaminant,
often reaching percentages that approximate the percent
of -cells (2,8). To assess the possible role of duct cells in
human islet cell implants, we have puriﬁed these cells
from human donor organs and examined their properties
in vitro as well as following transplantation in immune-
deﬁcient mice (9,10). It was thus found that human pan-
creatic duct cells react much more vigorously to cytokines
than the islet endocrine cells when comparing cellular
major histocompatibility complex II expression, induction
of nitric oxide (NO) synthase followed by production of
NO, and synthesis and subsequent release of the inﬂam-
matory cytokine tumor necrosis factor (TNF)- (11–13). In
addition, duct cells were shown to express CD40 that
rapidly activated nuclear factor-B upon ligation, lending
further support to the view that duct cells may actively
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2128 DIABETES, VOL. 57, AUGUST 2008contribute to the inﬂammatory process leading to diabetes
and/or to islet graft rejection (9,14). During these in vitro
studies on human duct cells, we noticed that they could
produce several cytokines, among which interleukin (IL)-8
(CXCL8) appeared more abundant. IL-8 is known as a
potent inducer of angiogenesis (15,16), involving effects on
chemotaxis, survival, and proliferation of tissue-speciﬁc
endothelial cells through interaction with its cognate G
protein–coupled receptors CXCR1 and CXCR2 (17,18). We
therefore compared the production of IL-8 and VEGF by
cultured human pancreatic duct cells and islet cell prepa-
rations and examined whether these duct cell products
exhibit angiogenic properties in laboratory models.
RESEARCH DESIGN AND METHODS
Cell isolation and culture. Human pancreatic duct cell and endocrine islet
cell fractions were prepared from donor organs that were procured by
transplant departments afﬁliated to Eurotransplant Foundation (Leiden, the
Netherlands). The organs were sent to the Beta Cell Bank in Brussels for
preparing -cell grafts in an approved clinical trial (8); procedures for organ
donation and for use of isolated fractions followed the guidelines of Euro-
transplant and of the ethics committees of Brussels Free University and the
Katholieke Universiteit Leuven. Endocrine islet cell fractions that did not
fulﬁll the criteria for transplantation were only released for associated
research projects when permission was granted; the latter was also needed for
the duct cell fraction. The techniques for isolation and culture of both
fractions have been previously described (8,13). Brieﬂy, the pancreas was
digested with collagenase and puriﬁed on a Ficoll gradient. The nonendocrine
fraction was recovered and cultured for 3–7 days as suspension in serum-free
HAM’s F-10 medium (Life Technologies, Paisley, U.K.) supplemented with 6.5
mmol/l glucose (Merck, Darmstadt, Germany), 0.5% BSA (Cohn analog BSA;
Sigma), 0.1 mg/ml streptomycin (Sigma Chemical, St. Louis, MO), 0.075 mg/ml
penicillin (Continental Pharma, Brussels, Belgium), and 0.3 mg/ml L-glutamine
(Sigma). At the end of this period, this fraction contained 90% CK19-positive
duct cells, 10% endocrine cells, and 1% acinar cells (as indicated by
amylase staining and electron microscopy). The endocrine islet cell fraction
was cultured in the same medium (19); after 1 week of culture, it contained
50–80% cells that were positive for insulin or glucagon and 20–50% CK19-
positive cells. For some experiments, fractions were enriched in either
endocrine or duct cells; this procedure involved a trypsin dissociation of an
islet fraction and subsequent ﬂow cytometry (ﬂuorescence-activated cell
sorter [FACS]) for separation of cells with high (endocrine) or low (duct)
cellular side scatter.
Conditioned medium preparation and cytokine measurement. Duct
cell–conditioned media were prepared for IL-8 and VEGF immunoassays and
for the rat aortic ring assay. They were collected after 24-h suspension culture
of the duct cell fraction at a density of 5  10
5 cells/ml in serum-free HAM’s
F10 (for enzyme-linked immunosorbent assay) or MCDB131 (for rat aortic
ring assay; Life Technologies). Conditioned media were clariﬁed by centrifu-
gation and stored at 20°C. Cell samples were taken for total RNA isolation
and quantitative real-time RT-PCR. A human-speciﬁc enzyme-linked immu-
nosorbent assay (R&D systems, Minneapolis, MN) was used to measure IL-8
and VEGF concentrations at minimum detectable doses of 3.5 ng/ml and 3.3
pg/ml, respectively.
Assessment of angiogenic effects. The angiogenic effect of cells or their
conditioned media was assessed in two models. The in vitro aortic ring assay
assesses the effect of solubilized agents on growth of endothelial cells and
their assembly into vessel-like structures (20). The in vivo chick embryo
chorioallantoic membrane (CAM) assay examines the effects of living cells on
these processes (21); to this end, sponges are used as cell carrier and placed
on the membrane, allowing the cellular secretory products to exert their
effects; this model was not suitable for testing our conditioned media as too
little volume can be inoculated.
Rat aortic ring assay. The rat aortic ring assay was performed as previously
described (20). In brief, aortas were removed from 6- to 10-week-old male
Wistar rats (Janvier, Le Genest Saint-Isle, France), sectioned into 1-mm-long
rings, and then embedded in gels of rat tail interstitial collagen (1.5 mg/ml,
Collagen R; Serva, Heidelberg, Germany) that had polymerized in cylindrical
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FIG. 1. IL-8 and VEGF expression and release by human pancreatic duct cell preparations during culture. Human pancreatic duct cells were
cultured for up to 15 days as described in RESEARCH DESIGN AND METHODS. Cell samples were taken for RNA isolation at indicated times. A:
Expression levels of IL-8 and VEGF were measured by real-time PCR and normalized to HPRT. Medium was sampled at the indicated times and
assayed for IL-8 and VEGF. B: Values are expressed as picograms per milliliter released by 10
3 cells over 24 h. Values are means of four
independent experiments  SE. P vs. start (day 0 or day 1): *P < 0.05.
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DIABETES, VOL. 57, AUGUST 2008 2129agarose wells (type VII; Sigma-Aldrich, St. Louis, MO). Each gel was kept at
37°C in 60-mm diameter bacteriologic Petri dishes containing 6 ml control or
conditioned medium. Positive controls consisted of culture medium with
recombinant human IL-8 (1 ng/ml) or recombinant human VEGF-A165 (20
ng/ml); both proteins were purchased from Peprotech (Rocky Hill, NJ). Each
condition was performed in triplicate; half of the medium volume was
replaced every other day. After 10 days, photographs were taken under phase
contrast (plan neoﬂuar 5/0.15; Axiovert 135 microscope equipped with
Axiocam MRc camera) and analyzed with Axiovision 3.1 (Carl Zeiss, Jena,
Germany) in order to count the number of microvessels and quantify their
total length. This study was approved by the local ethics committee.
Chick CAM assay. Fertilized white leghorn chicken eggs (Katholieke Uni-
versiteit Leuven animal house, Heverlee, Belgium) were incubated for 3 days
at 37°C before removing 3 ml of albumen to detach the shell from the
developing CAM. After making a window in the eggshell to expose the CAM,
it was covered with cellophane. Eggs were then further incubated until day 9,
when the test conditions were applied. Sterile absorbable gelatin sponges (1–2
mm
3; Hospithera, Brussels, Belgium) were impregnated with the indicated
pancreatic cell preparations and then placed on the CAM. PBS containing 0.1%
BSA (1 mg/ml, 50 	g/embryo) was used as a negative control and recombi-
nant human IL-8 (100 	g/ml, 5 	g/embryo) and recombinant human VEGF-
A165 (100 	g/ml, 5 	g/embryo) as positive controls. The windows were again
covered and the incubation continued until day 13, when angiogenesis was
assessed. Membranes were ﬁxed with 4% paraformaldehyde at room temper-
ature for 2 h. A large area around the contact or insertion sites was removed,
placed on a glass slide, and photographed under a Zeiss Axioplan 2 micro-
scope (Carl Zeiss) with a Kontron Electronik (Eching bei Mu ¨nchen, Germany)
image-analyzing system (KS400 version 3.00). To determine the number of
blood vessels, a grid containing three concentric circles with diameters of 4,
5, and 6 mm was positioned on the surface of the CAM and all vessels radiating
from the sample spot and intersecting the circles were blindly counted under
a stereomicroscope. In some experiments, sponges with cells were preincu-
bated with 500 ng of a neutralizing rabbit anti-human VEGF antibody
(Chemicon International, Temecula, CA), a mouse anti-human IL-8 antibody,
or a mouse anti-human CXCL1 antibody (R&D Systems) (30 min, 37°C, 5%
CO2) before implantation on the CAM.
Transplantation. Eight-week-old male normoglycemic nonobese diabetic
(NOD)/scid mice were used as transplant recipients (Katholieke Universiteit
Leuven breeding colony, Leuven, Belgium). Mice were kept under aseptic
conditions and had free access to pellet food and water. Animals were
anesthetized with intraperitoneal avertin (2,2,2-tribromoethanol, 500 mg/kg
body wt; Sigma-Aldrich) and grafts implanted under the kidney capsule (22).
Grafts consisted of a cultured human pancreatic duct cell fraction (74–88%
purity with 4–16% endocrine cells) or a cultured human endocrine islet cell
fraction (68–88% purity with 4–16% duct cells). Total cell number in each graft
was 5  10
6. Animals were killed at 15 min or 2, 8, 24, or 144 h posttrans-
plantation; graft-bearing kidneys were removed for mRNA analysis and/or
serum collected for analysis. The same human-speciﬁc enzyme-linked immu-
nosorbent assay kits (as described above) were used to measure human IL-8
and human VEGF concentrations in sera of graft recipients and sham controls.
This study was approved by the local ethics committee.
RNA isolation and quantitative real-time RT-PCR. Total RNA was
isolated from cultured cell fractions and from implants using Trizol (Life
Technologies). After treatment with Superscript II reverse transcriptase (Life
Technologies), real-time RT-PCR was performed for selected genes (23,24).
PCR were performed in the ABI Prism 7700 Sequence Detector (Perkin-Elmer/
Applied Biosystems, Foster City, CA) with a Gene-Amp PCR system 9600
(Perkin-Elmer). PCR ampliﬁcations were performed in triplicate. Human
cDNA was determined using the following sequences: for IL-8: forward
5
-TGGCAGCCTTCCTGATTTCT-3
, reverse 5
-TTAGCACTCCTTGGCAAAAC
TG-3
, and TaqMan Probe 5
-CAGCTCTGTGTGAAGGT-3
; for human VEGF:
forward 5
-ACCAAGGCCAGCACATAGAGA-3
, reverse 5
-CTTGCGCTTTCGT
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FIG. 2. Duct cells induce neogenesis of blood vessels in rat aortic ring assay. Isolated rat aortic rings were incubated for 10 days in control medium
(Ctrl) or medium with recombinant human IL-8 (1 ng/ml), recombinant human VEGF-A165 (20 ng/ml), a combination of both, or with 24-h duct
cell–conditioned medium (DuC). At day 10, rings were photographed. Total vessel numbers were counted and total vessel lengths were measured
as described in RESEARCH DESIGN AND METHODS. A: Values are the average of three aortic rings per condition  SE. P value vs. carrier alone (Ctrl);
*P < 0.05; #P < 0.001. Results come from at least three independent experiments. Representative photographs of each condition are shown in
B.
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, and TaqMan Probe 5
-CAGCACAACAAATGTGAATGCAGAC
CAA-3
. Primers and probes for the housekeeping gene human hypoxanthine-
phosphoribosyltransferase 1 (HPRT) were previously described (13). Data are
expressed as relative input copy number normalized to HPRT.
Statistics. Results are expressed as means  SE of n independent experi-
ments. Statistical analysis was performed using the SPSS computer program.
One-way ANOVA with post hoc least signiﬁcant difference was applied to
compare means of three or more groups. Differences were considered
signiﬁcant when P  0.05.
RESULTS
Human pancreatic duct cell preparations release
VEGF and IL-8 during culture. Cultured human pancre-
atic duct cell preparations were found to release IL-8 and
VEGF from the day of isolation and to sustain this activity
for at least 2 weeks; at day 15, the 24-h release of IL-8 was
threefold higher than at start (Fig. 1). The cultured cells
also exhibited a sustained mRNA expression for both
proteins over this period, with average levels that tended
to increase. When comparing individual donor cell prepa-
rations, we noticed a relatively large variability in absolute
levels of protein expression and release, which we have
not yet further examined in terms of possible underlying
reasons at the level of the donor or of the composition of
the isolate.
Duct cells induce VEGF- and IL-8–dependent neo-
genesis of blood vessels. To assess the angiogenic effect
of duct cell–released IL-8 and VEGF, we tested the angio-
genic potential of duct cells as well as of duct cell–
conditioned medium using recombinant human IL-8 and
VEGF as control conditions.
In the aortic ring assay, both recombinant human IL-8
and VEGF promote the outgrowth of vessel-like structures
over a 10-day culture period (Fig. 2). In presence of IL-8 (1
ng/ml) or VEGF (20 ng/ml), the number, as well as the total
length of vessels sprouting from the aortic rings, were
signiﬁcantly increased. Combination of both recombinant
proteins resulted in a cumulative effect, leading to a
threefold increase in the number of vessels and a ﬁvefold
increase in total vessel length. A stimulatory effect was
also observed after addition of culture medium that had
been conditioned for 24 h by duct cell aggregates; its
amplitude corresponded to 61% of the effect (for both
vessel count and total vessel length) measured for the
combination of IL-8 at 1 ng/ml plus VEGF at 20 ng/ml and
was comparable with that of VEGF alone at 20 ng/ml (Fig.
2).
In the chicken embryonic CAM assay, inoculation of 5
	g recombinant human VEGF or 5 	g human IL-8 mark-
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FIG. 3. Duct cells induce neogenesis of blood vessels in the CAM assay. Duct cells were grafted on CAMs at indicated concentrations with or
without anti-human IL-8 and anti-human VEGF neutralizing antibodies. BSA (50 g/embryo) was used as negative control and recombinant human
IL-8 (5 g/embryo) and VEGF (5 g/embryo) as positive controls. At day 13, the region around the implant was photographed. Values are the
average of three implants per condition  SE (of ﬁve independent experiments). P vs. negative control (50 g/embryo; 0.1% BSA) (A, upper
panel); P vs. 2.5  10
5 duct cell condition (A, lower panel). *P < 0.05; #P < 0.001. Representative photographs are shown in B. (Please see
http://dx.doi.org/10.2337/db07-1705 for a high-quality digital representation of this ﬁgure.)
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DIABETES, VOL. 57, AUGUST 2008 2131edly increased the number of allantoic vessels directed
toward the implant (Fig. 3). After 13 days, their number
was 2.5- to 3-fold higher than for sponges containing 50 	g
BSA. A similar increase was inducible with sponges con-
taining 2.5  10
5 human pancreatic duct cells (Fig. 3). This
duct cell effect was slightly stronger with 1 10
6 cells,
inducing four- and ﬁvefold more vessels than in the BSA
control or in eggs with sponges containing 0.1  10
5 cells,
respectively. Duct cell–induced allantoic vessel formation
was reduced by 55 and 41%, respectively, in presence of an
antibody against human VEGF or against human IL-8 but
not by an antibody against human CXCL1 (95% of control,
n  3, data not shown); when expressed in absolute
number of vessels these reductions did not reach statisti-
cal signiﬁcance probably as a result of the large variation
in the amplitude of IL-8 and VEGF release (section 1) and
the related duct cell effects (Fig. 3). However, the combi-
nation of both antibodies completely suppressed duct
cell–induced vessel formation (Fig. 3).
Contribution of duct cells to IL-8 and VEGF expres-
sion and to angiogenic effect in isolated human islet
preparations. When human duct cell fractions and islet
cell–enriched fractions isolated from the same donors
were compared for their IL-8 and VEGF expression, mRNA
levels of both factors were consistently higher in duct cell
preparations (Table 1). While each of the duct cell frac-
tions exhibited a high purity in CK19-positive cells (90%),
their individual IL-8 and VEGF expression level varied
markedly, with 20- to 60-fold higher values in one of the
preparations. The corresponding islet-enriched fractions
exhibited a similar variability in IL-8 and VEGF expression
(Table 1). Since human islet-enriched fractions contain
high percentages of nonendocrine cells that are CK19-
positive, we examined whether this expression and its
high variability was mainly located in the nonendocrine
cell population. Islet-enriched fractions were dissociated
and ﬂuorescence-activated cell sorted in a population of
nonendocrine cells (77–97% nongranulated cells in elec-
tron microscopy and 2–23% endocrine phenotype) and a
population of larger endocrine cells (91% cells with
endocrine granules in electron microscopy and 9% non-
granulated cells). Quantitative PCR analysis of IL-8 expres-
sion indicated that the nonendocrine cell population
exhibits a considerably higher IL-8 expression than the
endocrine cell population, and that it is also the cause for
the high variability in this expression (from 3.2 to 6.3
versus a range from 0.1 to 0.8 in the endocrine cell
population) (Table 1).
These observations led us to compare the angiogenic
effect of FACS-puriﬁed duct and islet endocrine cells. For
this experiment, we dissociated and ﬂuorescence-
activated cell-sorted transplant-grade islet preparations to
obtain a duct cell–puriﬁed population with 90% CK19-
positive cells and 5% endocrine cells and an endocrine
cell–puriﬁed population with 80% endocrine islet cells
and 20% CK19-positive cells. When tested at the same
cell concentrations (1, 2.5, and 5  10
5 cells) in the
chicken embryonic CAM assay, the duct cell fraction
induced a signiﬁcantly higher number of blood vessels
than the endocrine fraction (Table 2).
Human duct cell implants express and release IL-8
and VEGF. Since human islet cell grafts can contain a
high percentages of duct cells, it is conceivable that this
“contaminant” inﬂuences revascularization through its ex-
pression and release of angiogenic factors like IL-8 and
VEGF. Thus, we measured expression and release of both
compounds in human duct cell grafts (5  10
6 cells per
graft) that had been implanted under the renal capsule of
NOD/scid mice.
Implants were removed at different time points and
analyzed for their human IL-8 and VEGF expression by
quantitative real-time RT-PCR. Expression of both genes
TABLE 1
Correlation between presence of duct cells and expression of IL-8 and VEGF in human pancreatic cell preparations
Donor pancreatic fraction
Cellular composition (%) mRNA expression
Endocrine cells Duct cells IL-8/HPRT VEGF/HPRT
No. 1
Duct cell enriched 7 93 1.3 47.4
Islet cell enriched 79 21 0.1 9.9
No. 2
Duct cell enriched 1 98 0.6 25.4
Islet cell enriched 59 41 0.4 8.1
No. 3
Duct cell enriched 1 99 40.6 456.5
Islet cell enriched 50 50 11.0 319.1
No. 4
Duct cell enriched 2 97 3.2 36.2
Islet cell enriched 97 3 0.1 17.5
No. 5
Duct cell enriched 23 77 6.3 33.3
Islet cell enriched 96 4 0.7 8.8
No. 6
Duct cell enriched 5 95 4.6 14.4
Islet cell enriched 91 9 0.8 2.7
Pancreatic fractions enriched in duct cells or islet cells from the same donor were compared for their IL-8 and VEGF expression. Cells were
retrieved from culture, total RNA extracted, and reverse transcribed to cDNA. IL-8 and VEGF expression levels were measured by real-time
PCR and normalized to HPRT (donor numbers 1–3). Islet-enriched preparations were dissociated into single cells and ﬂuorescence-activated
cell sorted into duct cell–puriﬁed and endocrine cell–puriﬁed preparations prior to comparing their IL-8 and VEGF expression (donor
numbers 4–6).
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7- and 2.5-fold higher after 2 and 24 h, respectively, and
VEGF progressively increased to ﬁvefold higher levels
(Fig. 4). Six days after transplantation, the IL-8 mRNA
level was back to its start level, whereas the VEGF mRNA
level was still 61% higher, although not signiﬁcantly differ-
ent from basal control (Fig. 4).
Serum of recipients of duct cell grafts was assayed for
human IL-8 and VEGF. None of the proteins were detected
in sham-operated animals (data not shown) or at 15 min
posttransplantation. At 120 min, all recipients presented
markedly elevated human IL-8 levels (100–600 pg/ml), but
these decreased thereafter (Fig. 4). In six of eight recipi-
ents, human VEGF was also clearly detected in the serum,
at levels ranging from 100 to 400 pg/ml, and remained
present in the 24-h samples (Fig. 4). The failure to detect
human IL-8 and VEGF at 15 min posttransplantation might
reﬂect in part the delay of diffusion from the fresh non
vascularized implant to the blood. For IL-8, upregulation of
mRNA during the ﬁrst posttransplant hours seems also
related to the appearance of the protein in the circulation.
The IL-8 and VEGF expression in transplanted duct cells
was higher than that in islet cell–enriched implants pre-
pared from the same donors, which is consistent with the
differences observed in the isolated preparations (Fig. 5).
DISCUSSION
The present study demonstrates that human pancreatic
duct cells can produce IL-8 and VEGF, two compounds
that are known for their angiogenic activity (15,25). Both
proteins are released at biologically relevant levels during
culture of duct cell–enriched fractions that are prepared
from human donor organs. To assess the angiogenic effect
of duct cell–released IL-8 and VEGF, we tested duct cells
and duct cell–conditioned medium in the aortic ring assay
and in the chick embryo CAM assay. In both models,
addition of IL-8 or VEGF induces the formation of mi-
crovessels with an increased potency when two factors
were combined. Duct cells and their medium were found
to induce similar effects and these appeared mediated by
IL-8 and VEGF, since they were suppressed by neutralizing
antibodies to these cytokines.
The IL-8 and VEGF release by isolated human duct cells
is not reactive to the preparative procedure but is consti-
tutive, as shown by the persistent expression and release
of both proteins during culture. The two cytokines re-
mained also expressed following transplantation of a
cultured duct cell fraction under the kidney capsule of
immune-deﬁcient NOD/scid mice. They were even de-
tected in the circulation of these animals, be it only during
the ﬁrst day posttransplantation. This short episode of
elevated circulating levels does not exclude that both
proteins remain produced and locally released at later
times but indicates that the immediate posttransplant
period favors their release, possibly as an effect of the
hypoxic and/or inﬂammatory environment, which is
known to induce IL-8 and VEGF production (26,27). When
comparing data from independent experiments, we ob-
served a high variation in the mRNA expression level of
both proteins. This might reﬂect interindividual variations
as seen in vitro (present study) and in other studies. VEGF
production appears for example related to polymorphism
in its gene promoter (28) and IL-8, usually barely detect-
able in normal tissue, was found to increase 10- to 100-fold
under stress or proinﬂammatory cytokines (29). The
present preparations were also obtained from donors of
different age and sex, following various disease histories
and organ preservation conditions. Finally, although the
duct cell preparations appeared quite pure in light of their
CK19-expressing cells, they might still be composed of
different subpopulations with consequences on the rates
of IL-8 and VEGF production.
IL-8 belongs to the family of CXC chemokines that are
inducible by inﬂammatory mediators such as IL-1, TNF-,
and bacterial products (30,31) and that have been impli-
cated in early phases of tissue repair (32). Besides its
angiogenic effect, IL-8 was found to recruit and activate
monocytes to vascular lesions (33). Tissue inﬁltration by
lymphocytes and macrophages is known to mediate local
expression of VEGF, which promotes endothelial cell
proliferation, migration, and microvascular networking
(34). These processes were not investigated in the trans-
planted mice; the revascularization process is difﬁcult to
quantify and it is also uncertain whether immune-deﬁcient
recipients represent an adequate model for studying in-
ﬂammatory and repair reactions.
The ﬁnding that human pancreatic duct cells can pro-
duce and release IL-8 and VEGF at levels that can stimu-
late angiogenesis might be relevant in human islet cell
transplantation. In our experience, cultured human islet
cell grafts contain 13–40% nongranulated CK19-positive
cells that correspond to duct cells (8). This contaminating
fraction is the main source of the IL-8 and VEGF produc-
tion by the islet-enriched fraction. When compared with
the expression levels in puriﬁed human endocrine islet
cells, puriﬁed human duct cells generate 6- to 28-fold more
IL-8 and 2- to 5-fold more VEGF. This difference was also
reﬂected following transplantation in mice.
TABLE 2
Comparison of angiogenic effects of duct cell–puriﬁed and endo-
crine cell–puriﬁed fractions in the CAM assay
Inoculate
Number of blood
vessels per implant P
Duct cell puriﬁed
10
6 cells
0.10 37.0  0.0 NS
0.25 42.5  3.5 0.05
0.50 41.0  1.4 0.01
Endocrine cell puriﬁed
10
6 cells
0.10 14.0  15.6
0.25 18.0  8.7
0.50 24.0  1.4
Concentration (	g/ml)
BSA
1,000 9.3  2.7
Recombinant human VEGF
100 27.3  7.6 0.001*
Recombinant human IL-8
100 23.2  5.9 0.001*
Data are the average of three implants per condition  SE (of two to
ﬁve independent experiments). Islet preparations were dissociated
to single cells and ﬂuorescence-activated cell sorted into duct
cell–puriﬁed and endocrine cell–puriﬁed preparations before inocu-
lation on CAMs at the indicated cell numbers. At day 13, the region
around the implant was photographed and the number of vessels was
counted. P vs. endocrine cell–puriﬁed preparation. *P vs. negative
control (1,000 	g/ml; 0.1% BSA).
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important for the revascularization and survival of im-
planted -cells (7). So far, -cells have been considered as
the driver of such process (35), but the evidence is still
incomplete. Rat islet grafts were indeed shown to express
increased VEGF levels during the ﬁrst days following
transplantation (36), which can be explained by a hypoxia-
induced transcriptional activation and mRNA stabilization
in the -cells (37). That -cell release of VEGF may
promote angiogenesis was demonstrated by the improved
vascularization and function of rodent islet grafts in which
an increased VEGF expression was under control of the
insulin promoter or had been induced by gene transfer
(7,38). Surprisingly, blockade of VEGF signaling by an
antagonist of VEGF-KDR/ﬂk-1 did not impair the revascu-
larization of transplanted islets (39), which was not sufﬁ-
cient to disregard a VEGF-regulated process but
suggestive for further investigating the mechanisms under-
lying the revascularization of islet cell grafts. In fact,
mouse islet implants under the kidney capsule or in the
liver or spleen exhibit a much lower vascular density than
pancreatic islets (40); they are, however, surrounded by a
well-vascularized connective tissue that may provide a
richer source of proangiogenic compounds. The present
study shows that human pancreatic duct cells are a more
potent source of VEGF than -cells and that this is also the
case for IL-8, another angiogenic factor. Whether, and if
so, to which extent, the environment of contaminating
duct cells can help the revascularization of a human -cell
implant is not yet known. It is likely that the microenvi-
ronment of the implant will not only regulate the produc-
tion of angiogenic factors such as IL-8 and VEGF but also
that of as-yet-unidentiﬁed angiostatins and of other inﬂam-
matory substances that can inﬂuence the survival of the
-cells. Previous work has shown that human duct cells
can produce other inﬂammatory products like NO and
TNF- (12,13) and participate in the coagulation process
(41). Angiogenic effects at the site of implantation can also
be inﬂuenced by immune suppressive agents. Since rapa-
mycin has been shown to suppress IL-8 expression (42)
and to block VEGF effects (43), it needs to be assessed for
possible negative inﬂuences on the revascularization of
human islet grafts; its antiangiogenic effect might even be
involved in its inhibitory action on -cell regeneration
(44), which is known to depend on interactions with
vascular components (45). The currently used in vitro and
in vivo models provide the tools to investigate these
questions. Our observations demonstrate that duct cells
should not be considered as passive bystanders in this
process and further support their earlier proposed role in
islet transplantation (44).
I
L
-
8
 
(
p
g
/
m
l
)
0
200
400
600
NS
NS NS
#
0
5
10
15
20
25
I
L
-
8
 
/
 
H
P
R
T
NS
NS
NS
NS
#
0
100
200
300
V
E
G
F
 
/
 
H
P
R
T
NS
NS
NS
#
#
basal 0.25 2 8 24 144
Time after Transplantation (h)
0.25 2 8 24 144
V
E
G
F
 
(
p
g
/
m
l
)
*
0
100
200
300
400
NS
ND
*
Time after Transplantation (h)
A B
FIG. 4. Human duct cell grafts express IL-8 and VEGF after transplantation. Human duct cells were transplanted under the kidney capsule of
NOD/scid mice. A: At indicated times, grafts were explanted and total RNA extracted and reverse transcribed to cDNA. IL-8 and VEGF gene
expression levels were assessed by real-time PCR and normalized to HPRT. Values are means of four animals per time point. Figure represents
three independent experiments. P vs. basal condition: *P < 0.05; #P < 0.001. At indicated time points, blood was taken from transplanted animals
and serum assayed for human IL-8 and VEGF. Each dot represents an individual serum concentration value. Horizontal lines represent median.
B: P vs. initial time point: *P < 0.05; #P < 0.001.
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